Myriad myRisk® advances hereditary cancer testing by providing comprehensive knowledge of cancer risks and management options.

The panel has a ~40-50% relative increase in mutation detection over the single-syndrome testing approach.¹˒²

Myriad myRisk evaluates 25 clinically actionable genes associated with 8 common cancer sites

Genes Breast Ovarian Colorectal Endometrial Melanoma Pancreatic Gastric Prostate Other
BRCA1, BRCA2
MLH1, MSH2, MSH6, PMS2, EPCAM
STK11
APC, BMPRIA, SMAD4
MUTYH
CDKN2A, CDK4
TP53
PTEN
CDH1
PALB2, ATM
CHEK2
NBN
BARD1
BRIP1, RAD51C
RAD51D

All 25 genes included on the panel meet at least one of the following criteria:

  • Absolute cancer risk increase of at least 5%
  • 2- to 3-fold increase in cancer risk over the general population
  • Existing society guidelines around management or a change in management is inferred based on the level of risk associated with mutations detected in the genes

No matter your patients’ results, you can have confidence that the known genetic factors have been evaluated.

The Myriad myRisk report presents the genetic test results first and clear guideline-based management considerations on subsequent pages. In reports with a positive or negative genetic test result, the myRisk Management Tool blends the genetic information with family history to provide guideline-based management considerations.

myRisk Genetic Result

The second part of the report, the myRisk Management Tool provides test and patient summary information, cancer risks, management guidance, and information for your patient’s family.

myRisk Genetic Result

More Info on the Myriad myRisk Test Results


Genetic Results + Management Tool = Optimized Patient Care

Data presented at ASCO in 2014 by Lucy R. Langer, MD, from U.S. Oncology illustrated that 25% of patients with a negative genetic result still had medical management changes based on information gained from the Myriad myRisk Management Tool. Additionally, 78% of patients with a positive genetic result had management changes based on information gained from the Myriad myRisk Management Tool.³


Multigene panel testing provides accurate results and clear management recommendations for patients with increased cancer risks

Testing with the Myriad myRisk hereditary cancer panel:

  • Provides confidence in knowing your patients’ risks and clear direction on the recommended management options to reduce their risks
  • Rapid turnaround time of 14-21 days for test results
  • The Myriad myRisk Management Tool provides a summary of national guidelines to help you optimize your patients’ care
  • Myriad’s commitment to patients and their families is demonstrated with its industry-leading variant classification program, myVision™. Myriad’s myVision is the world’s most advanced approach to the classification and reclassification of variants of uncertain significance -using more validated classification methods and higher classification standards than any other laboratory.

Know the red flags associated with hereditary cancer:

Red Flags for Hereditary Cancer
An individual with a personal or family history of any ONE of the following:

MULTIPLE

A combination of cancers on the same side of the family

  • 2 or more: breast / ovarian / prostate / pancreatic cancer
  • 2 or more: colorectal / endometrial / ovarian / gastric / pancreatic / other(i.e. ureter / renal pelvis, biliary tract, small bowel, brain, sebaceous adenomas
  • 2 or more: melanoma / pancreatic

YOUNG

Any 1 of the following cancers at age 50 or younger

  • Breast cancer
  • Colorectal cancer
  • Endometrial cancer

RARE

Any 1 of these rare presentations at any age

  • Ovarian cancer
  • Breast: male breast cancer or triple negative breast cancer
  • Colorectal cancer with abnormal MSI/IHC, MSI associated histology††
  • Endometrial cancer with abnormal MSI/IHC
  • 10 or more gastrointestinal polyps*

††Presence of tumor infiltrating lymphocytes, Crohn’s-like lymphocytic reaction, mucinous/signet-ring differentiation, or medullary growth pattern.
*Adenomatous type.
Assessment criteria based on medical society guidelines. For these individual medical society guidelines, go to www.MyriadPro.com/guidelines.
Family members include first-, second-, and third-degree blood relatives on both your mother and father’s sides.
Certain ancestries may have greater risk for hereditary cancer syndromes (e.g., Ashkenazi Jewish ancestry)


Be confident in knowing your patients’ comprehensive cancer risks and specific medical management options with the Myriad myRisk Hereditary Cancer Panel

Order a Myriad myRisk test kit Today


References

  1. Prevalence of Gene Mutations Among Hereditary Breast and Ovarian Cancer Patients Using a 25 Gene Panel, Nadine Tung et. al. Presented at ACMG in March 2014
  2. Multi-gene panel testing in patients suspected to have Lynch syndrome, Matthew B. Yurgelun et. al. Presented at ASCO June 2014
  3. Langer et. al. 25-gene panel testing and integrated risk management tool impacts medical management in hereditary cancer syndrome evaluation, ASCO 2014

Leave a Reply

Your email address will not be published. Required fields are marked *